<abstract xmlns="http://www.w3.org/1999/xhtml"><p> Nonsteroidal anti-inflammatory drugs (NSAIDs) are authorized for the relief of pain and inflammation in a wide range of conditions including the discomfort associated with headaches, osteoarthritis, rheumatoid arthritis, and menstrual pain and are available by prescription or over-the-counter (OTC). We reviewed common adverse effects of NSAIDs (especially those related to cardiovascular [CV] system) along with NICE (National Institute for Health and Care Excellence), EMA (European Medicines Agency), and the FDA (U.S. Food and Drug Administration) guidelines for safe and effective use of particular NSAIDs. Furthermore, we examined the NSAIDs market in Lithuania in a period between June 2016 and May 2017 and discussed how well recommendations mentioned above were followed. We emphasized that there was a high percentage of diclofenac prescribed in Lithuania while international guidelines encourage prescribing ibuprofen or naproxen for their relatively lower CV risk. Reviewing past trials, we observed that despite existing guidelines no single NSAID could be considered to be the safest one due to a lack of superiority trials</p></abstract>

Nonsteroidal anti-inflammatory drugs (NSAIDs) are authorized for the relief of pain and inflammation in a wide range of conditions including the discomfort associated with headaches, osteoarthritis, rheumatoid arthritis, and menstrual pain and are available by prescription or over-the-counter (OTC). We reviewed common adverse effects of NSAIDs (especially those related to cardiovascular [CV] system) along with NICE (National Institute for Health and Care Excellence), EMA (European Medicines Agency), and the FDA (U.S. Food and Drug Administration) guidelines for safe and effective use of particular NSAIDs. Furthermore, we examined the NSAIDs market in Lithuania in a period between June 2016 and May 2017 and discussed how well recommendations mentioned above were followed. We emphasized that there was a high percentage of diclofenac prescribed in Lithuania while international guidelines encourage prescribing ibuprofen or naproxen for their relatively lower CV risk. Reviewing past trials, we observed that despite existing guidelines no single NSAID could be considered to be the safest one due to a lack of superiority trials

Review: The choice and cardiovascular safety of particular nonsteroidal anti-inflammatory drugs

Seminars in Cardiovascular Medicine

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Nonsteroidal anti-inflammatory drugs (NSAIDs) are authorized for the relief of pain and inflammation in a wide range of conditions including the discomfort...

Review: The choice and cardiovascular safety of particular nonsteroidal anti-inflammatory drugs

Data publikacji: 01 wrz 2018

Zakres stron: 16 - 21

Otrzymano: 05 wrz 2017

Przyjęty: 14 lut 2018

DOI: https://doi.org/10.2478/semcard-2018-0003

Słowa kluczowe
NSAID, cardiovascular risk, diclofenac safety, naproxen, NSAID guidelines

© 2018 Jonas Černeckis et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Review: The choice and cardiovascular safety of particular nonsteroidal anti-inflammatory drugs

Data publikacji: 01 wrz 2018

Zakres stron: 16 - 21

Otrzymano: 05 wrz 2017

Przyjęty: 14 lut 2018

DOI: https://doi.org/10.2478/semcard-2018-0003

Słowa kluczoweNSAID, cardiovascular risk, diclofenac safety, naproxen, NSAID guidelines

© 2018 Jonas Černeckis et al., published by Sciendo

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 License.

Słowa kluczowe
NSAID, cardiovascular risk, diclofenac safety, naproxen, NSAID guidelines